Advertisement

High Blood Pressure & Cardiovascular Prevention

, Volume 25, Issue 4, pp 407–413 | Cite as

Effect of Amlodipine/Valsartan Versus Nebivolol/Valsartan Fixed Dose Combinations on Peripheral and Central Blood Pressure

  • Selvia M. Farag
  • Hoda M. Rabea
  • Hesham B. Mahmoud
Original Article
  • 46 Downloads

Abstract

Introduction

Although hypertensive drugs may have the same effect on peripheral blood pressure, they vary in their effect on central blood pressure and its indices.

Aim

To evaluate efficacy of fixed-dose combination of amlodipine 10 mg/valsartan 160 mg versus nebivolol 5 mg/valsartan 160 mg in grade 2 or more hypertensive patients assessed by peripheral and central blood pressure.

Methods

A prospective, open label, randomized study done in the outpatient cardiology clinic at Beni-Suef University Hospital. A total of 137 patients continued the study; group I (n = 75) received Amlodipine 10 mg/Valsartan 160 mg (A/V) and group II (n = 62) received Nebivolol 5 mg/Valsartan 160 mg (N/V). Peripheral, central blood pressure and its indices were measured at baseline, after 6 and 12 weeks.

Results

The two combinations reduced peripheral and central BP (P < 0.0001) after 6 and 12 weeks. A/V combination significantly reduces central Pulse Pressure (PP) after 6 and 12 weeks (− 8.53 ± 13.80 and − 10.17 ± 11.29 (P < 0.0001) respectively), while N/V showed its efficacy in reducing central PP after 12 weeks (− 7.03 ± 13.10, P = 0.005). A/V combination was more effective in reducing Pulse Wave Velocity (PWV) after 6 and 12 weeks; P < 0.0001 vs P = 0.004. After 6 weeks, N/V was more effective in reducing Augmentation Index (AIx) (− 6.00 ± 10.94 (P = 0.002) vs. − 3.44 ± 9.80 (P = 0.026)) while after 12 weeks A/V did not show any significance (P = 0.085).

Conclusions

Both treatment groups lowered patients’ peripheral, central blood pressure after 6 and 12 week of treatment, but Amlodipine/Valsartan combination was more effective. Both treatments exerted different effects on central indices.

Keywords

Combination therapy Peripheral blood pressure Central blood pressure PWV AIx 

Notes

Compliance with Ethical Standards

Ethical approval

The study was approved by Faculty of Medicine - Beni-Suef University Research Ethical Committee “FM-BSU REC” and was registered (FWA00015574).

Informed consent

Informed consent was obtained from each patient before participation in the trial.

Conflict of interest

We declare that we have no conflict of interest.

References

  1. 1.
    Frank J. Managing hypertension using combination therapy. Am Fam Physician. 2008;77(9):1279–86.PubMedGoogle Scholar
  2. 2.
    Mancia G, Fagard R, Narkiewicz K, Redán J, Zanchetti A, Böhm M et al. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2013;31(10):1925–38.CrossRefGoogle Scholar
  3. 3.
    Whelton PK, Carey RM, Aronow WS, Casey DE, Jr., Collins KJ, Dennison Himmelfarb C et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2018;71(19):e127–e248.Google Scholar
  4. 4.
    Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113(9):1213–25.CrossRefPubMedGoogle Scholar
  5. 5.
    Roman MJ, Devereux RB, Kizer JR, Lee ET, Galloway JM, Ali T, et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension. 2007;50(1):197–203.CrossRefPubMedGoogle Scholar
  6. 6.
    Vlachopoulos C. Combination therapy in hypertension: from effect on arterial stiffness and central haemodynamics to cardiovascular benefits. Artery Res. 2016;14:27–35.CrossRefGoogle Scholar
  7. 7.
    Agabiti-Rosei E, Porteri E, Rizzoni D. Arterial stiffness, hypertension, and rational use of nebivolol. Vasc Health Risk Manag. 2009;5:353–60.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–104.CrossRefPubMedGoogle Scholar
  9. 9.
    McEniery CM, Cockcroft JR, Roman MJ, Franklin SS, Wilkinson IB. Central blood pressure: current evidence and clinical importance. Eur Heart J. 2014;35(26):1719–25.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Weber T, Wassertheurer S, Rammer M, Maurer E, Hametner B, Mayer CC, et al. Validation of a brachial cuff-based method for estimating central systolic blood pressure. Hypertension. 2011;58(5):825–32.CrossRefPubMedGoogle Scholar
  11. 11.
    Smith Timothy R, Philipp Thomas, Vaisse Bernard, Bakris George L, Wernsing Margaret, Yen Joseph, et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens. 2007;9:355–64.CrossRefGoogle Scholar
  12. 12.
    Philipp T, Smith TR, Glazer R, Wernsing M, Yen J, Jin J, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther. 2007;29(4):563–80.CrossRefPubMedGoogle Scholar
  13. 13.
    Kizilirmak P, Berktas M, Uresin Y, Yildiz OB. The efficacy and safety of triple vs dual combination of angiotensin II receptor blocker and calcium channel blocker and diuretic: a systematic review and meta-analysis. J Clin Hypertens. 2013;15(3):193–200.CrossRefGoogle Scholar
  14. 14.
    Deedwania P, Shea J, Chen W, Brener L. Effects of add-on nebivolol on blood pressure and glucose parameters in hypertensive patients with prediabetes. J Clin Hypertens. 2013;15(4):270–8.CrossRefGoogle Scholar
  15. 15.
    Weber MA, Basile J, Stapff M, Khan B, Zhou D. Blood pressure effects of combined beta-blocker and angiotensin-converting enzyme inhibitor therapy compared with the individual agents: a placebo-controlled study with nebivolol and lisinopril. J Clin Hypertens. 2012;14(9):588–92.CrossRefGoogle Scholar
  16. 16.
    Ishak J, Rael M, Punzi H, Gradman A, Anderson LM, Patel M, et al. Additivity of nebivolol/valsartan single-pill combinations versus other single-pill combinations for hypertension. J Clin Hypertens. 2018;20(1):143–9.CrossRefGoogle Scholar
  17. 17.
    Neutel JM, Giles TD, Punzi H, Weiss RJ, Li H, Finck A. Long-term safety of nebivolol and valsartan combination therapy in patients with hypertension: an open-label, single-arm, multicenter study. JASH. 2014;8(12):915–20.PubMedGoogle Scholar
  18. 18.
    Ruilope L, Schaefer A. The fixed-dose combination of olmesartan/amlodipine was superior in central aortic blood pressure reduction compared with perindopril/amlodipine: a randomized, double-blind trial in patients with hypertension. Adv Ther. 2013;30(12):1086–99.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Vaz-de-Melo OR, Giollo-Júnior TL, Martinelli DD, et al. Nebivolol reduces central blood pressure in stage I hypertensive patients: experimental single cohort study. Sao Paulo Med J. 2014;132(5):290–296.CrossRefPubMedGoogle Scholar
  20. 20.
    Dhakam Z, McEniery CM, Brown MJ, Wilkinson AIB. A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens. 2008;26(2):351–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Kampus P, Serg M, Kals J, Zagura M, Muda P, Karu K, et al. Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension. 2011;57(6):1122–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Boutouyrie P, Beaussier H, Achouba A, Laurent S, Trialists E. Destiffening effect of valsartan and atenolol: influence of heart rate and blood pressure. J Hyperten. 2014;32(1):108–14.CrossRefGoogle Scholar
  23. 23.
    Boutouyrie P, Achouba A, Trunet P, Laurent S, Group ET. Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study. Hypertension. 2010;55(6):1314–22.CrossRefPubMedGoogle Scholar
  24. 24.
    Studinger P, Tabak AG, Chen CH, Salvi P, Othmane TE, Torzsa P, et al. The effect of low-dose carvedilol, nebivolol, and metoprolol on central arterial pressure and its determinants: a randomized clinical trial. J Clin Hypertens. 2013;15(12):910–7.CrossRefGoogle Scholar
  25. 25.
    Shi R, Liu K, Shi D, Liu Q, Chen X. Effects of amlodipine and valsartan on blood pressure variability and pulse wave velocity in hypertensive patients. Am J Med Sci. 2017;353(1):6–11.CrossRefPubMedGoogle Scholar
  26. 26.
    Mahmud A, Feely J. Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. Am J Hypertens. 2008;21(6):663–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Fogari R, Zoppi A, Derosa G, Mugellini A, Lazzari P, Rinaldi A, et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens. 2007;21(3):220–4.CrossRefPubMedGoogle Scholar
  28. 28.
    Weiss RJ, Stapff M, Lin Y. Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial. Am J Cardiovasc Drugs. 2013;13(2):129–40.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Selvia M. Farag
    • 1
  • Hoda M. Rabea
    • 2
  • Hesham B. Mahmoud
    • 3
  1. 1.Cardiovascular DepartmentBeni-Suef Hospital UniversityBeni-SuefEgypt
  2. 2.Clinical Pharmacy Department, Faculty of PharmacyBeni-Suef UniversityBeni-SuefEgypt
  3. 3.Beni-Suef Hospital UniversityBeni-SuefEgypt

Personalised recommendations